# Sub-analysis of perfusion balloon predilatation with intracoronary nicorandil vs. distal protection for acute coronary syndrome: A comparative evaluation

**Authors:** Masataka Yoshinaga, Takashi Muramatsu, Takashi Uwatoko, Akane Miyazaki, Takuo Toriya, Yuji Matsuwaki, Masato Ishikawa, Yuko Ukai, Yohei Kobayashi, Katsuyoshi Ito, Hideaki Ota, Yoshihiro Sobue, Eiichi Watanabe, Hideo Izawa

PMC · DOI: 10.20407/fmj.2025-009 · Fujita Medical Journal · 2025-11-05

## TL;DR

A study compared two methods for treating acute coronary syndrome and found that one method significantly reduced complications and improved efficiency.

## Contribution

The study introduces a novel approach using perfusion balloon predilatation with nicorandil as an alternative to conventional distal protection.

## Key findings

- The PB group had significantly fewer slow-flow or no-reflow events compared to the DP group.
- Procedure time was shorter in the PB group.
- The PB group used less contrast volume than the DP group.

## Abstract

Slow-flow or no-reflow events occur as a complication during percutaneous coronary intervention for acute coronary syndrome (ACS). A previous study demonstrated that prolonged perfusion balloon (PB) predilatation combined with intracoronary administration of nicorandil attenuates this phenomenon. This subanalysis compared the efficacy of the PB approach with that of conventional distal protection (DP).

The study had a retrospective, single-center, observational design and included patients who underwent percutaneous coronary intervention for ACS between April 2020 and April 2022. The patients were divided into a PB group and a DP group. The PB group underwent thrombus aspiration, followed by 3 minutes of predilatation using the Ryusei® PB, with simultaneous intracoronary administration of nicorandil 2 mg without a DP device and subsequent placement of a drug-eluting stent. The DP group underwent direct stenting or predilatation with a standard balloon combined with a DP device without a PB. Primary endpoints included the incidence of slow-flow or no-reflow events.

Sixty-four patients with ACS were enrolled (PB group, n=32; DP group, n=32). The incidence of slow-flow or no-reflow events was significantly lower in the PB group (3.1% vs. 46.8%, p<0.01), as was procedure time (87.1±26.4 minutes vs. 108.6±42.3 minutes, p=0.02) and volume of contrast used (186.0±65.0 mL vs. 228±75.8 mL, p=0.02).

PB predilatation with intracoronary nicorandil significantly reduced the number of slow-flow or no-reflow events, shortened procedure time, and reduced the volume of contrast used. This method could be at least as effective as DP.

## Linked entities

- **Chemicals:** nicorandil (PubChem CID 47528)
- **Diseases:** acute coronary syndrome (MONDO:0005542)

## Full-text entities

- **Diseases:** thrombus (MESH:D013927), ACS (MESH:D054058)
- **Chemicals:** Ryusei  PB (-), nicorandil (MESH:D020108)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862346/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862346/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862346/full.md

---
Source: https://tomesphere.com/paper/PMC12862346